Goldman-Backed Biotech Attovia Raises $289 Million in US IPO
Attovia Therapeutics Inc., an early-stage drug developer focused on immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range.
This is a summary aggregated from Bloomberg Markets. Read the complete article on the original site:
Read full article at Bloomberg Markets
